Form 4: Emergent BioSolutions Director Sells Shares to Cover Tax Obligations

Emergent BioSolutions Inc. Director Keith Katkin sold 7,844 shares of common stock on May 23, 2025, at a weighted average price of $6.3 per share, to satisfy tax obligations related to RSU vesting.

Summary

• Keith Katkin, a Director of Emergent BioSolutions Inc. (EBS), sold 7,844 shares of the company's common stock.
• The transaction occurred on May 23, 2025.
• The shares were sold at a weighted average price of $6.3 per share, with prices ranging from $6.22 to $6.35.
• The sale was executed under a Rule 10b5-1 trading plan, which was established on November 8, 2024.
• The primary purpose of the sale was to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs) on May 22, 2025.
• Following this transaction, Mr. Katkin beneficially owns 86,431 shares of Emergent BioSolutions common stock.

Sentiment

Score: 5

Explanation: The transaction is neutral as it's a routine sale for tax obligations under a pre-arranged plan, not indicative of a change in sentiment towards the company's prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to market conditions.

Negatives

• A director selling shares, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Such transactions are common for executives and directors managing their equity compensation across various sectors.

Comparison to Industry Standards

• NA. This document reports an individual insider transaction, which is not typically compared to industry-wide financial performance benchmarks or specific projects. The sale for tax obligations related to RSU vesting is a standard practice for executives receiving equity compensation across various industries.

Stakeholder Impact

• Shareholders: A minor reduction in a director's direct ownership, which is generally neutral given the stated tax purpose and the pre-arranged nature of the transaction.

Key Dates

Recommendation

Keywords

Emergent BioSolutions, EBS, Keith Katkin, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director, Tax Obligations, RSU Vesting, Common Stock